Article info
PDFReview
Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know
- Correspondence to Dr Claire Roddie, University College London, London WC1E 6BT, UK; c.roddie{at}ucl.ac.uk
Citation
Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know
Publication history
- Accepted April 22, 2020
- First published June 5, 2020.
Online issue publication
July 28, 2020
Article Versions
- Previous version (5 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- CAR-T treatment for hematological malignancies
- Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- Unexpected neurologic complications following a novel lymphoma treatment ‘expected’ to give rise to neurologic toxicity
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Cardiotoxicities of novel cancer immunotherapies
- What is CAR T-cell therapy?